The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Open accessAbstract
Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IFN γ and TNF α are key effector cytokines that contribute to anti-tumour immune responses 9,11,27-30 , and genes associated with IFN and TNF signaling pathways contribute to immune evasion 4,9,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Chronic IFN signaling can also promote an immune suppressive environment126.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [126]
In the citing paper
“The expression of PD-L1 and MHC II, which may cause exhaustion by binding to T-cell programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3), respectively, is regulated by tumor interferon (IFN) signaling.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“In solid tumors, a tumor IFN–stimulated gene signature termed ISG.RS is associated with a multigenic program of T-cell exhaustion and worse outcomes after immune checkpoint blockade.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“One part of this program is to increase tumor expression of multiple T-cell ligands that lead to exhaustion of T cells infiltrating the TME.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“When tumors express a gene signature (ISG.RS) consisting of genes coordinately activated by multiple types of IFN, a multigenic therapy resistance program is activated.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“Recently, the Minn group elucidated how chronic IFN signaling mediates immunosuppression and resistance to radiation and immune checkpoint inhibitor therapy in solid tumors.2,24,54”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“interferon signaling is of central importance to antitumor immune response43.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I?
Haugh, A. M., & DAUD, A. I. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0373 · Cited by 4
Nie, A.-Y., Xiao, Z.-H., Deng, J., Li, N., Hao, L., Li, S.-H., & Hu, X.-Y. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i2.98556 · Cited by 3
Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy
Chiu, P.-H., Lai, K.-C., Wang, H.-L., Chang, Y.-W., Wu, W.-C., Chen, T.-H., Tsai, Y., Song, J.-H., Sun, N.-Y., Chau, G., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102448 · Cited by 3
Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity
Zhou, X., Geyer, F. K., Takimoto, J., Kolmar, H., & Rabinovich, B. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1718321 · Cited by 3
Wang, H.-H., Nan, L.-Y., Zheng, Y., & Guo, J. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04302-8 · Cited by 3
The Immune Landscape of Acral Melanoma: From Basic to Clinical
Jiang, L., & Zhang, Z. Y. (2026) · Cancer Medicine · doi:10.1002/cam4.71615 · Cited by 3
Gu, C., He, R., Yin, X., Wang, J., Yang, J., Gao, J., Xie, R., Geng, Y., Lu, J., Ke, Z., et al. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01222-5 · Cited by 3
Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies
Lu, W., Ojha, R., Rana, M., Gautam, V., Li, J.-Y., & Wang, S.-A. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2689287 · Cited by 3
Chen, P., Long, J., Zhang, J., Xie, F., Wu, W., Tian, Z., Zhang, S., & Yu, K. (2024) · Inflammation Research · doi:10.1007/s00011-023-01833-w · Cited by 3
Wang, Y., Peng, M.-Z., Xu, Y.-L., Ying, Y., Tang, L.-H., Xu, H., He, J., Liu, L., & Wang, W.-Q. (2024) · Discover Oncology · doi:10.1007/s12672-024-01420-3 · Cited by 3
The underlying mechanism and therapeutic potential of IFNs in viral-associated cancers
Zhu, Y., Li, Z., Yu, Z.-L., Lu, Y., Liu, J., Chen, J.-R., & Xie, Z.-Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123301 · Cited by 4
Xu, J., Sussman, J., Yang, A. G., Yoshimura, S., Hu, J., Chen, C., Vincent, T. L., Bandyopadhyay, S., Li, E. Y., Lim, T., et al. (2025) · Blood · doi:10.1182/blood.2025028566 · Cited by 3
The IFN-high phenotype: A biomarker-driven breakthrough in colorectal cancer treatment
Allonsius, L., Kelecom, L., & Laoui, D. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102025 · Cited by 3
Wang, J., Zhang, D., Yang, Y., Zhang, X., Cao, Y., Zhang, C., Yan, Y., Zhao, J., & Chen, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152605 · Cited by 3
Jiaojiao, S., He, Y., Li, Y., Liu, G., Li, Q., Li, S., & Yu, H. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/1218969 · Cited by 3
The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma
Tang, G., Liu, J., Qi, L., & Li, Y. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15504 · Cited by 3
Mori, S., Nakamura, K., Shimamura, M., & Ohe, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206257 · Cited by 3
Wellhausen, J., Röhl, L., Berszin, M., Krücken, I., Zebralla, V., Pirlich, M., Stoehr, M., Wiegand, S., Dietz, A., Wald, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1473897 · Cited by 3
Gold digging: Searching for gut microbiota that enhances antitumor immunity
Hou, F., Pan, Z., Yang, R., Zhi, F., & Bi, Y. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30272 · Cited by 2
Kankuri‐Tammilehto, M., Perasto, L., Pyrhönen, S. O., & Salminen, E. K. (2023) · Anticancer Research · doi:10.21873/anticanres.16431 · Cited by 3
Secreted cytokines provide local immune tolerance for human stem cell-derived isletsPreprint
Gerace, D., Zhou, Q., Kenty, J. H.-R., Sintov, E., Wang, X., Boulanger, K. R., Li, H., & Melton, D. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.09.487072 · Cited by 3
Chibaya, L., Lusi, C. F., DeMarco, K. D., Kane, G. I., Brassil, M. L., Parikh, C. N., Murphy, K. C., Li, J., Naylor, T. E., Cerrutti, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.18.558307 · Cited by 3
Antigenic cancer persister cells survive direct T cell attackPreprint
Wang, M., Mauch, B. E., Williams, A. F., Barazande-Pour, T., Hoffmann, F. A., Harris, S. H., Lathrop, C. P., Turkal, C. E., Yung, B. S., Paw, M. H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.14.643359 · Cited by 3
Deciphering Cell Fate and Clonal Dynamics via Integrative Single-Cell Lineage ModelingPreprint
Fu, Y., Mathew, D., Wang, M., Chen, X. E., Lin, K., Schaff, D. L., Shaffer, S. M., Pardoll, D. M., Jackson, C., & Zhang, N. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.01.673503 · Cited by 3
Wu, Q., Li, W., Liu, H., Xue, Y., Huang, K., Pourghadamyari, H., & Liu, Z. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101383 · Cited by 2
Zhou, R., Mayberry, R., Firmin, T., Sanders, A. J., Brouwer, C., Maher, J. F., & Mukherjee, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1618415 · Cited by 2
Sun, R., Wang, X., Fang, Z., Li, Z., Dai, C., Liu, J., Xiao, J., Wu, H., Zhang, Y., & Feng, H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149632 · Cited by 2
DNA-Damaging Agents Induce PD-L1 Expression through the Src-STAT1-IRF1 Pathway
Suzuki, Y., Nishibu, S., Nohara, A., Onuma, I., Zhou, Y., Sakurai, H., & Yokoyama, S. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00610 · Cited by 3
Wang, H., Wen, Z., Jia, Y., Tong, X., Wang, W., Wang, Z., Jin, H., Gao, X., Tao, X., Cheng, H., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117708 · Cited by 2
Discovery of the first dual PD-L1/JAK inhibitor with enhanced in vivo antitumor immunity
Wang, Z., He, H., Xu, J., Liao, X., Tan, J., Xu, C., Tan, J., Zhang, L., Wang, Q., Yang, X., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118605 · Cited by 2
Li, J., Jiang, W., Tu, G., Zhong, Z., Luo, Z., Horng, T., & Miao, C. (2026) · British Journal of Cancer · doi:10.1038/s41416-025-03319-4 · Cited by 2
Çelik, S., Kavak, E. E., Zeynelgil, E., İmamoğlu, G. İ., Dilli, İ., Karatlı, S., Atak, M., Altınbaş, M., & Eren, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072475 · Cited by 2
Brett, J. O., Herman, P. E., Mayer, E. L., Bardia, A., & Wander, S. A. (2022) · Current Breast Cancer Reports · doi:10.1007/s12609-022-00461-3 · Cited by 2
[Advances of Immunotherapy Resistance and Coping Strategies in Non-small Cell Lung Cancer].
Jing, Y., Zeng, H., Cheng, R., Tian, P., & Li, Y. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.03 · Cited by 2
Heterogeneity in functional genetic screens: friend or foe?
Vredevoogd, D. W., & Peeper, D. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162706 · Cited by 3
Khanolkar, A., Liu, G.-R., & Schneider, B. M. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813937 · Cited by 2
Strategies and rules for tuning TCR-derived therapy
Mo, G., Lu, X., Wu, S., & Zhu, W. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.27 · Cited by 2
Mukund, K., Alva-Ornelas, J. A., Maddox, A. L., Murali, D., Veraksa, D., Saftics, A., Tomšič, J., Frankhouser, D. E., Razo, M., Jovanović‐Talisman, T., et al. (2024) · Cancers · doi:10.3390/cancers16030553 · Cited by 2
IRF4 as a molecular biomarker in pan-cancer through multiple omics integrative analysis
Tan, Y., Yang, Y., Zhang, M., Li, N., Hu, L., Deng, M., Xiao, Y., Wang, Y., Tian, F., & Sun, R. (2025) · Analytical Methods · doi:10.1039/d4ay02269f · Cited by 2
Emerging new immune checkpoint inhibitors in solid tumor immunotherapy
Poorkhani, A., Tajaldini, M., Ahmadi, F., Tahmasebifar, A., Azadehrah, M., Azadehrah, M., Ghamoushiramandi, A., Amiri, R. S., & Khori, V. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04131-w · Cited by 3
Calabrese, L. H., & Calabrese, C. M. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000684 · Cited by 2
RIP(K)ing away immunotherapy resistance
Patel, M. A., & Tavazoie, S. F. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.010 · Cited by 2
Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade
Moise, J., Murthy, J. J., Dabir, D., Yu, S., Kisto, F., Herron, E., & Aulakh, S. (2022) · Immuno · doi:10.3390/immuno2040041 · Cited by 2
Interferón-gamma: vías de señalización y sus implicaciones en el cáncer
Zamora-Salas, S. X., Robles-Villarruel, M. L., Macías‐Silva, M., Álvarez-Sánchez, M. E., & Tecalco-Cruz, Á. C. (2023) · TIP Revista Especializada en Ciencias Químico-Biológicas · doi:10.22201/fesz.23958723e.2023.533 · Cited by 1
MicroRNA‐Responsive DNA Dendrimer Acts as a Smart STING Signal Amplifier
WU, R. T., Xue, Y., Zhan, J., Feng, Z., Zhu, J., & Zhang, J. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300088 · Cited by 2
Novel Methods to Overcome Acquired Resistance to Immunotherapy
Zhao, X., Yuan, C., Rieth, J. M., Wangmo, D., & Subramanian, S. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_4 · Cited by 2
Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade
Vackova, J., Piatakova, A., Poláková, I., & Šmahel, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051806 · Cited by 2
Translational Development and Testing of Theranostics in Combination with Immunotherapies
Carlson, P. M., & Morris, Z. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-81261-4_12 · Cited by 2
Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapyPreprint
Jain, M. D., Ziccheddu, B., Coughlin, C. A., Faramand, R. G., Griswold, A. J., Reid, K. M., Landgren, O., Locke, F. L., Maura, F., Davila, M. L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.25.457649 · Cited by 2
Ramos, A., Koch, C. E., Liu, Y., Hellinger, R. D., Kyung, T., Abbott, K. L., Fröse, J., Goulet, D. R., Gordon, K. S., Larson, R. C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.15.480217 · Cited by 2
Chow, R. D.-W., Michaels, T., Bellone, S., Hartwich, T. M. P., Bonazzoli, E., Iwasaki, A., Song, E., & Santin, A. D. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4059524 · Cited by 2
Victoria, S., Castro, A., Pittini, Á., Olivera, D., Russo, S., Cebrián, I., Mombrú, Á. W., Osinaga, E., Pardo, H., Segovia, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.02.506404 · Cited by 2
Zhang, D. Y., Wang, X., Sun, Y. Y., Cui, Q., Nelson, E. J., Zhang, Z., Huang, B. L., Giles, J. R., Thokala, R., Connolly, D. R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.03.616537 · Cited by 2
Self-citationOpenDVP: An experimental and computational framework for community-empowered deep visual proteomicsPreprint
Nimo, J., Fritzsche, S., Valdes, D. S., Trinh, M., Pentimalli, T. M., Klingeberg, M., Schallenberg, S., Klauschen, F., Herse, F., Florian, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.13.662099 · Cited by 2
Reghupaty, S. C., Kanwal, S., Mendoza, R. G., Davis, E., Li, H., Lai, Z., Dozmorov, M. G., Faison, M. O., Siddiqui, R. A., & Sarkar, D. (2023) · Cancers · doi:10.3390/cancers15174283 · Cited by 1
Subbarayan, K., Bieber, H., Massa, C., Rodríguez, F. A. E., Hossain, S. M. A. A., Neuder, L., Wahbi, W., Salo, T. A., Tretbar, S., Al‐Samadi, A., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06177-z · Cited by 1
Palli, E., Lavigne, M. D., Verginis, P., Alissafi, T., Anastasopoulou, A. N., Lyrarakis, G., Kirkwood, J. M., Gogas, H. J., & Ziogas, D. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529707 · Cited by 1
Xie, Y., Wang, R., Xu, M., Chen, J., Tan, W. H., Chen, Y., Bai, Y., Wu, N., Wu, F., Xu, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06455-w · Cited by 1
One Step Ahead: Preventing Tumor Adaptation to Immune Therapy
Braverman, E. L., Mognol, G. P., Minn, A. J., Vignali, D. A. A., & Varner, J. A. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-481556 · Cited by 1
Self-citationContrasting interferon-mediated antiviral responses in human lung adenocarcinoma cells
Esparza, M. A., Zahed, S. S. E., Karakus, U., Niederstrasser, H., Gao, B., Batten, K. G., Shay, J. W., Posner, B. A., Hirsch, F. R., Girard, L., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00469-25 · Cited by 1
Applications of single-cell transcriptomics: updated insights in endometrial cancer
Xiao, S., Li, H., Liu, J., Xie, X., Xu, H., Gong, Z., & Zhong, S. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04032-7 · Cited by 1
Zhang, Z., Xu, A., Zhou, Q., Wen, F., Chen, F., Chen, H., Wang, H., Chen, L., Ju, Z., & Ge, Y. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae065 · Cited by 1
Ekedahl, H., Sigurjonsdottir, G., Bergqvist, V., Båtshake, B., Carneiro, A., & Marsal, J. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.44298 · Cited by 1
Research progress in the construction and application of immunotherapy resistance models
Li, H., Wang, S., Li, X., Wu, H., Feng, Y., Hu, X., Zhang, L., & Dong, X. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04221-x · Cited by 1
Cui, J., Wang, J., Li, X., Wang, L., Mao, X., Lyv, R., Yan, W., Xu, J., Zhou, J., Du, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202510816 · Cited by 2
Mosquim, S., Zamore, M., Vallon‐Christersson, J., Rydén, L., & Levander, F. (2026) · Breast Cancer Research · doi:10.1186/s13058-025-02173-9 · Cited by 1
The interplay between cytokines and immune checkpoints in breast cancer therapy
Wu, Y., Zhu, Y. F., Cang, Q., Shaibu, Z., Kong, L., Zhou, Q., Li, X., & Yin, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189539 · Cited by 1
Zuo, M., Li, H., Chen, N., Guo, Z., & Wan, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1737569 · Cited by 1
Marco, S., Fernández, M., Honorato, B., Juanarena, N., Sainz, C., Andueza, A., Gould, D., Anderson, S., de Andrea, C., Domínguez, P. P., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.02.013 · Cited by 1
The JAK/STAT Pathway in Cancer: From Molecular Mechanisms to Clinical Applications
Liao, Y., Wei, Q., Song, H., Zeng, H., Qi, C., Meng, Y., Zhang, Y., Zhang, Y., Li, W., Li, Y., et al. (2026) · MedComm – Oncology · doi:10.1002/mog2.70063 · Cited by 1
Sævarsson, T., de Lomana, A. L. G., Sánchez, Ó., Brynjolfsson, S. F., Steingrı́msson, E., & Einarsdottir, B. O. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02840-0 · Cited by 1
Onieva, J. L., Pérez-Ruíz, E., Vilkki, V., Berciano‐Guerrero, M., Figueroa-Ortiz, L. C., Zalabardo, M., Martínez-Gálvez, B., Barragán, I., & Rueda‐Domínguez, A. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2650234 · Cited by 1
Perineural invasion: A neuroimmune axis mediating immunotherapy resistance across malignancies
Guo, J., Hu, Z., Wu, L., Liu, L., Li, Z., Xiong, L., & Yu, D. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116636 · Cited by 1
Viral Mimicry by Repeats Mediates Evolutionary Trade-Offs in Cancer-Immune Coevolution
Sun, S., & Greenbaum, B. D. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-2187 · Cited by 1
Mitochondrial double-stranded RNA fuels pancreatic cancer growth via RIG-I/TLR3 inflammation
Milcarek, A. T., Yeon, M., Esposito, C., Kulkarni, P., Kossenkov, A. V., Madžo, J., Faustino, A. M., Tang, H.-Y., Storaci, A. M., Palleschi, A., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2528281123 · Cited by 2
Jiang, Y., Luo, J., Liu, C., Xue, W., liu, J., Wang, M., Shi, S., Yin, X., & li, X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114992 · Cited by 1
Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy
Kirkland, A. P., Shah, M., & Spruck, C. (2026) · Biomolecules · doi:10.3390/biom16050709 · Cited by 1
Chemically Masked aPD‐L1‐Sialidase Conjugate for Tumor‐Specific Desialylation and Immunotherapy
Zeng, J., Han, S., Wang, X., Tan, L., Pan, X., Cao, B., Li, Z., Li, Z., Liu, T., & Wang, Y. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.8361803 · Cited by 1
Cashman, H. P., & Turtle, C. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1819591 · Cited by 1
Zhou, Y., Geng, H., Xu, Y., Hong, Y., Mei, B., Wu, H., Jin, X., Ye, M., Wang, Y., Shen, Z., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03768-6 · Cited by 1
Vasilakou, A., Loizon, S., Dubois, M., Laurent, P., Sisirak, V., & Duluc, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1847012 · Cited by 2
Vaccination-enabled immune readiness for checkpoint blockade
Bautista, J., & López-Cortés, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1790344 · Cited by 1
Pan, J., Li, B., Lin, R., Fang, C., Lau, L., Hong, Z., & Chen, Y. (2026) · International Journal of Oncology · doi:10.3892/ijo.2026.5932 · Cited by 1
Niu, X., & Yu, B. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.09.006 · Cited by 1
Jiang, J., & Zhao, Y. (2021) · Journal of Oncology · doi:10.1155/2021/5533923 · Cited by 1
Small Molecule Inhibitors of Interferon‐Induced JAK‐STAT Signalling
Thoidingjam, L. K., Blouin, C. M., Gaillet, C., Brion, A., Solier, S., Niyomchon, S., Marjou, A. E., Mouasni, S., Sepulveda, F. E., Basile, G. D. S., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202205231 · Cited by 1
Li, Z., Yang, H., Liu, J., Li, L., & Wang, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.947364 · Cited by 1
Inducible nitric oxide synthase 2 (NOS2) and antitumor γδ-T cells
Leyva, B. K., & Bonavida, B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13342-8.00007-7 · Cited by 1
Ye, J., Tang, H., Xie, C., Han, W., Shen, G., Qian, Y., & Xu, J. (2023) · PeerJ · doi:10.7717/peerj.15634 · Cited by 1
Zhao, Z., Zhang, L., Zhang, X., Yue, Y., Liu, S., Li, Y., Ban, X., Zhao, C., & Jin, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-41421-w · Cited by 1
Wei, K.-K., Du, Z.-X., Deng, J., Yang, J.-W., & Chen, H. (2023) · Journal of Immunology Research · doi:10.1155/2023/8776892 · Cited by 1
Role of interferon dependent and independent signaling pathways: Implications in cancer
Spada, S., & Ganguly, A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.06.004 · Cited by 1
Januskinaseinhibitoren für dermatologische Erkrankungen
Solimani, F., & Ghoreschi, K. (2024) · Die Dermatologie · doi:10.1007/s00105-024-05406-8 · Cited by 1
Lee, H. W., & Sung, H. H. (2025) · Journal of Urologic Oncology · doi:10.22465/juo.255000300015 · Cited by 1
Precision Medicine in Immunoradiotherapy
Feng, J., Peng, J., Qiu, H., Hu, K., Guo, X., Liu, B., Bu, L., & Wu, Q. (2025) · Springer eBooks · doi:10.1007/978-981-96-3659-4_11 · Cited by 1
Gromeier, M., & Brown, M. C. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00040-24 · Cited by 1
HLA molecules: Another challenge for CAR T cell therapy
Salih, I., Fakhkhari, M., Berrougui, H., Khalil, A., Benabdellah, K., Atilla, E., & Sadki, K. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103547 · Cited by 1
Nanotechnology for Diagnosis, Imaging, and Treatment of Head and Neck Cancer
Ebrahimi, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-69859-1_4 · Cited by 1
Kabarriti, R., & Guha, C. (2021) · Springer eBooks · doi:10.1007/978-981-16-1815-4_2 · Cited by 1
Radionuclide Therapy and Immunomodulation
Anderson, R. L., & Vallis, K. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-81261-4_11 · Cited by 1
Metadata
- Authors
- Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., Gangadhar, T. C., Amaravadi, R. K., Schuchter, L. M., Feldman, M. D., Ishwaran, H., Vonderheide, R. H., Maity, A., Wherry, E. J., & Minn, A. J.
- Affiliations
- University of Pennsylvania (US)
- University of Miami (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Minn, Andy J.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 167
- Issue
- 6
- Pages
- 1540-1554.e12
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5385895
- OpenAlex
- W2558219863
- Cited by
- 1,216
- References
- 42
- Citations by year
- 2026: 150 · 2025: 124 · 2024: 127 · 2023: 135 · 2022: 128 · 2021: 140 · 2020: 140 · 2019: 114 · 2018: 92 · 2017: 64 · 2016: 1
- FWCI
- 48.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo
- Funders
- Melanoma Research Alliance
- Parker Institute for Cancer Immunotherapy
- Robertson Foundation
- Cancer Research Institute Irvington Fellowship
- NIH (P50CA174523, R01CA163739, R01CA158186, P30CA016520, U19AI082630, R01AI105343, U01AI095608, P01AI112521)
- Basser Research Center for BRCA
- Abramson Cancer Center Translational Center of Excellence in Pancreatic Cancer
- Department of Defense Era of Hope Scholar (W81XWH-09-1-0339)
- NCI (R01CA172651)
- Merck
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitor resistance, type I interferon, interferon-gamma, PD-1 pathway, PD-L1, STAT1, interferon-stimulated genes, T cell inhibitory receptors, T cell exhaustion, radiotherapy, tumor immune microenvironment, resistance biomarkers, anti-PD-1 therapy
- MeSH terms
- Animals, Humans, Interferons, Melanoma, Neoplasm Transplantation, T-Lymphocytes, Radioimmunotherapy, Drug Resistance, Neoplasm, Cell Line, Tumor, STAT1 Transcription Factor, Mice, B7-H1 Antigen, CTLA-4 Antigen, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
